TIMP-2 traditionally inhibits MMP-2 and -9, but, in aggressive cancers, TIMP-2 uniquely binds and activates pro-MMP-2 and MT1-MMP to stimulate MAPK/ERK signaling (68, 71). Here, MMP2 is linked to cancer.